Journal issues > Issue 2, March 2024 > Haematological highlights from ESMO 2023

Haematological highlights from ESMO 2023

SUMMARY

Once more, the European Society for Medical Oncology (ESMO) dedicated a session to haematological malignancies during its last meeting in October 2023. This session revealed novel immunotherapeutic strategies, such as activating γ9δ2 T cells to treat haematological cancers and using trifunctional natural killer (NK) cell engagers to eliminate CD123+ tumour cells. Additionally, promising results were observed with the combination of toripalimab and radiotherapy in treating extranodal NK/T cell lymphoma. Furthermore, genetic analyses identified genetic alterations with prognostic value for anti-PD-1 therapy in peripheral T-cell lymphomas (PTCL). Finally, a large cohort study examined treatment outcomes in primary ocular adnexal MALT lymphoma (POAML) patients.

(BELG J HEMATOL 2024;15(2):62–5)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top